Skip to main content

Table 1 DMBA-induced mammary gland tumor formation in WT, CORT-KO and SST-KO mice by whole-mount analysis

From: Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode

 

WT

CORT-KO

SST-KO

 

LF (n = 39)

HF (n = 43)

LF (n = 33)

HF (n = 24)

LF (n = 23)

HF (n = 30)

Whole-mount analysis

Tumor

3 %

5 %

14 %##

13 %

4 %$

3 %$

Hyperplasia

16 %

35 %**

10 %

25 %**

13 %

38 %***

Normal

81 %

60 %**

76 %

63 %

83 %

59 %**

Percentage of mice that were not included in the studya

35 %

24.5 %

21.4 %

40 %

30.3 %

23 %

  1. **p <0.01, ***p <0.001, for mice fed a low fat (LF) diet vs high fat (HF) diet (within the same genotype); ## p <0.01 in wild-type (WT) vs knockout (KO) mice (within the same diet group); $ p <0.05) in cortistatin (CORT)-KO vs somatostatin (SST)-KO (within the same diet group). aMice that died during the 3 weeks of 7, 12 dimethylbenz[α]anthracene (DMBA) administration or during the weeks immediately subsequent, due to the toxicity of this compound and/or the invasiveness of the method used to deliver DMBA, were not included in the study